In Brief: Genzyme Seprafilm
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Seprafilm: Follow-up at 8-12 weeks post-surgery shows that 51% of abdominal surgery patients treated with the bioresorbable membrane do not develop adhesions, according to results of a study presented Oct. 24 at the American College of Surgeons meeting in New Orleans. The success rate compares to a 6% rate for control patients who did not receive the membrane in the 11-center, 183-subject, prospective, randomized, blinded study. Cambridge, Massachusetts-based Genzyme says it plans to submit the data, along with data from a study of gynecologic surgery, in a PMA for Seprafilm...